Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy

Triple-negative breast cancer (TNBC) is a highly aggressive disease and of poor prognosis. It is very important to identify novel biomarkers to predict therapeutic response and outcome of TNBC. We investigated the association between polymorphisms in PARP1 gene and clinicopathological characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yuqian, Liao, Yulu, Li, Jun, Xiong, Jianping, Fan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192942/
https://www.ncbi.nlm.nih.gov/pubmed/32355298
http://dx.doi.org/10.1038/s41598-020-64473-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192942/
https://www.ncbi.nlm.nih.gov/pubmed/32355298
http://dx.doi.org/10.1038/s41598-020-64473-8

Ejemplares similares